Information Provided By: 
Fly News Breaks for March 15, 2019
QGEN
Mar 15, 2019 | 05:53 EDT
UBS analyst Daniel Brennan started Qiagen with a Neutral rating and $42 price target. Both consensus and the company's long-term guidance call for revenue growth acceleration in 2019 and 2020 with growth sustained at 8.5% in 2021, Brennan tells investors in a research note. With Qiagen trading near 10-year high multiples, the stock's valuation reflects achievement of these targets, says the analyst. However, Brennan believes "this is certainly not assured," given the company's dependency upon several new diagnostic products.
News For QGEN From the Last 2 Days
There are no results for your query QGEN
